Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company that employs a structure-based drug discovery approach to develop novel small molecule medicines for challenging targets in immunology, oncology, and metabolic diseases. Founded in 2009, the company utilizes advanced computational and experimental techniques to design precision therapeutics. Its strategy involves advancing programs to key inflection points before establishing major partnerships with larger pharmaceutical firms.

History

The company was established in 2009 by venture capitalists Bruce Booth of Atlas Venture and Peter Barrett of Third Rock Ventures, along with entrepreneur Alan Crane. Its founding was based on a model pioneered by Schrödinger to apply computational chemistry and molecular modeling at scale. Early operations were incubated within the venture capital firms before becoming an independent entity. A significant early milestone was a major collaboration with Celgene in 2014 focused on an ACC inhibitor for nonalcoholic steatohepatitis. In 2016, the company entered a strategic partnership with Gilead Sciences to develop therapies for oncology and inflammatory diseases, leading to a substantial acquisition by Gilead in 2022.

Business model and partnerships

The company operates a "asset-centric" model, focusing its internal resources on advancing a small number of programs through preclinical and early clinical proof-of-concept. It relies heavily on strategic alliances with global pharmaceutical partners for later-stage development, commercialization, and global distribution. Its most notable partnership was with Gilead Sciences, which began in 2016 and culminated in Gilead's $405 million upfront acquisition of the company's TYK2 program in 2022. Earlier, a 2014 pact with Celgene on its ACC program resulted in a $1.2 billion acquisition by Celgene in 2019. The company has also received funding from investors including Atlas Venture, Access Industries, and Bill & Melinda Gates Foundation.

Key programs and pipeline

The company's pipeline has featured programs targeting enzymes and pathways implicated in severe diseases. Its lead asset, now owned by Gilead Sciences, is a highly selective allosteric inhibitor of TYK2 for autoimmune conditions like psoriasis and psoriatic arthritis. Another major program was an ACC inhibitor for nonalcoholic steatohepatitis, which was advanced by Celgene and later Bristol Myers Squibb. Additional disclosed programs include a HPK1 inhibitor for immuno-oncology and a CD73 inhibitor aimed at modulating the tumor microenvironment. The company continues to advance new candidates from its discovery platform into development.

Technology platform

The core of the company's approach is an integrated computational drug discovery engine that combines physics-based modeling, machine learning, and medicinal chemistry. This platform is designed to tackle difficult-to-drug targets, such as those with shallow, featureless binding sites or high homology to other proteins. It utilizes free energy perturbation calculations to predict binding affinity with high accuracy, guiding the design of selective small molecules. The platform is supported by capabilities in cryo-electron microscopy, X-ray crystallography, and biophysics to rapidly validate and optimize compound designs.

Leadership and team

The company is led by Chief Executive Officer Jeb Keiper, who previously held roles at Mersana Therapeutics and Shire plc. Its scientific co-founders include renowned computational chemistry expert Ajay N. Jain of the University of California, San Francisco. The leadership team and board comprise veterans from the biotechnology and venture capital sectors, including partners from Atlas Venture and SR One. The company's research and development efforts are supported by a team of scientists with deep expertise in computational biology, structural biology, and translational medicine.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Biotechnology companies established in 2009